This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 13About Prevnar 13Mechanism of ActionSerotype coverageIncidence of IPD and Colonization dataExperienceImmunogenicityDosingDosingDosingEfficacy and Safety ProfileEfficacy and Safety ProfileEfficacy profileSafety profileGuidelinesGuidelinesGuidelinesResourcesResourcesMaterialsVideos
Product MonographImportant Safety Information 
Complete Prevnar® 13’s 3-dose schedule before your patient turns oneFor routine pediatric immunization programs to help protect against invasive pneumococcal disease (IPD) due to serotypes contained in the vaccine1-3* Are your patients getting the full schedule?

With your support, a timely and complete 3-dose schedule of Prevnar 13 can continue to help protect infants against IPD caused by 13 serotypes of S. pneumoniae.

 Learn more about dosing LoadingConsider Prevnar 13 for your patients

Recognized by NACI for children 2 to 12 months1,2*

Routine immunization generally occurs at 2, 4 and 12 months of age.2,3

 Learn more about the NACI recommendations for use of Prevnar 13 in infants  Loading

Serotype coverage

Prevnar 13 has indicated serotype coverage for the following 13 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.3

 Learn more about serotype coverage Loading

Prevnar 13 has 12+ years on the Canadian market†

 Learn more about Prevnar 13’s experience in Canada LoadingTitlePrevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) is indicated for active immunization of infants and children from 6 weeks to 5 years of age (prior to the 6th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia) and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. Important Safety Information

Relevant warnings and precautions:

  • Immunocompromised individuals may have a reduced antibody response to the vaccine.
  • Safety and immunogenicity data on Prevnar 13 are not available for individuals in certain immunocompromised groups (e.g., those with malignancy or nephrotic syndrome) and vaccination should be considered on an individual basis. Some safety and immunogenicity data are available in individuals with sickle cell disease, HIV infection, or hematopoietic stem cell transplant.
  • Individuals with acute severe febrile illness.
  • Individuals with thrombocytopenia or any coagulation disorder, or receiving anticoagulant therapy.
  • May not protect all individuals from pneumococcal disease.
  • Risk of apnea in very premature (≤30 weeks of gestation) infants.
  • Potential for higher incidence of fever (≥38.0°C to ≤39.0°C), convulsions (with or without fever), and hypotonic-hyporesponsive episode (HHE) with concomitant Infanrix hexa® use in infants.
  • The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) in children ≥24 months of age with sickle cell disease, asplenia, HIV infection, chronic illness, or who are otherwise immunocompromised. Data on sequential vaccination with Prevnar 13 followed by 23-valent pneumococcal polysaccharide vaccine are not available. Data on sequential vaccination with Prevnar (7-valent) vaccine followed by PPSV23 are limited.
  • Prophylactic administration of acetaminophen may reduce the immune response to Prevnar 13 after the infant series.

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available on request by calling 1-800-463-6001.NACI: National Advisory Committee on Immunization.Please see the Canadian Immunization Guidelines for complete recommendations.Clinical significance is unknown.References:An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Update on the Use of Conjugate Pneumococcal Vaccines in Childhood. Can Commun Dis Rep. 2010;36(ASC-12):1–21.Health Canada. Canadian Immunization Guide Part 4 – Active Vaccines: Pneumococcal Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a7. Accessed April 29, 2019.Prevnar® 13 Product Monograph. Pfizer Canada ULC.Public Health Agency of Canada. Vaccination coverage in Canadian children: Results from the 2015 Childhood National Immunization Coverage Survey (CNICS). Available at: http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-156-2018-eng.pdf. Accessed May 14, 2019.
PP-PRV-CAN-0016-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN